乳腺癌治疗后发生后续原发性肺癌的风险及影响因素:基于四百万病例的系统综述与两项荟萃分析
该系统综述与两项荟萃分析检索了PubMed、EMBASE和Web of Science数据库,比较乳腺癌患者与一般人群发生肺癌的风险,并探索乳腺癌治疗后发生原发性肺癌的影响因素。第一项荟萃分析纳入15项研究共1,161,979例患者,女性乳腺癌患者发生后续肺癌的风险显著高于一般人群(SIR=1.25,p<0.001)。第二项荟萃分析纳入22篇文章共3,090,620例患者,吸烟(OR=9.73,p<0.001)和放疗(RR=1.40,p<0.001)为后续肺癌的危险因素,化疗(RR=0.69,p=0.002)、雌激素受体阳性(RR=0.93,p=0.014)和孕激素受体阳性(RR=0.86,p<0.001)为保护因素;亚组分析显示放疗仅增加同侧肺癌风险(RR=1.27,p=0.001)。
要点
- 女性乳腺癌患者后续肺癌风险显著高于一般人群(SIR=1.25,p<0.001)。
- 吸烟(OR=9.73)与放疗(RR=1.40)是后续肺癌的危险因素。
- 化疗及ER/PR阳性为保护因素,放疗仅增加同侧肺癌风险(RR=1.27)。
核心结论
- 乳腺癌患者较一般人群更易发生肺癌,后续原发性肺癌风险受吸烟、放疗、化疗及ER/PR状态影响。
研究设计与样本
- 第一项荟萃分析纳入15项研究共1,161,979例患者,合并SIR比较乳腺癌与一般人群的肺癌风险。
- 第二项荟萃分析纳入22篇文章共3,090,620例患者,合并RR或OR评估临床病理参数与后续肺癌风险的关联。
主要发现
- 女性乳腺癌患者后续肺癌风险显著高于一般人群(SIR=1.25,p<0.001)。
- 吸烟(OR=9.73,p<0.001)和放疗(RR=1.40,p<0.001)为后续肺癌的危险因素。
- 化疗(RR=0.69,p=0.002)、ER阳性(RR=0.93,p=0.014)和PR阳性(RR=0.86,p<0.001)为保护因素。
- 基于乳腺癌与肺癌相对位置(同侧 vs 对侧)的亚组分析显示,放疗仅增加同侧肺癌风险(RR=1.27,p=0.001)。
临床怎么用
- 对乳腺癌幸存者应关注后续原发性肺癌风险,尤其是有吸烟史或接受放疗者。
- 放疗相关风险主要表现为同侧肺癌风险增加,随访时应结合照射野评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To compare the risk of developing lung cancer between patients with breast cancer and the general population and explore the risk factors for the development of primary lung cancer after treatment for breast cancer. METHODS: The PubMed, EMBASE, and Web of Science databases were searched from the establishment date to October 11, 2020. Two separate meta-analyses were performed: one focused on studies reporting the risk of subsequent lung cancer after breast cancer and one focused on studies exploring the risk factors for subsequent lung cancer in patients with breast cancer. The standardized incidence ratios with 95% confidence intervals were combined to compare the risk of developing lung cancer between patients with breast cancer and the general population. The relative risks (RRs) or ORs with 95% confidence intervals were combined to assess the association of clinicopathological parameters with the risk of developing lung cancer after breast cancer. All statistical analyses were conducted by STATA 12.0. RESULTS: A total of 15 studies involving 1,161,979 patients were eventually included in the first meta-analysis, and the pooled results indicated that female patients with breast cancer revealed a significantly higher risk of developing subsequent lung cancer (standardized incidence ratio = 1.25, p < 0.001). In addition, a total of 22 articles involving 3,090,620 patients were included in the second meta-analysis. The pooled results indicated that smoking (OR = 9.73, p < 0.001) and radiotherapy (RR = 1.40, p < 0.001) were risk factors for developing subsequent lung cancer in patients with breast cancer, and chemotherapy (RR = 0.69, p = 0.002), positive estrogen receptor status (RR = 0.93, p = 0.014) and positive progesterone receptor status (RR = 0.86, p < 0.001) were protective factors. Meanwhile, subgroup analysis based on the relative position of the breast and lung cancers (ipsilateral versus contralateral) was conducted, which indicated that radiotherapy only increased the risk of ipsilateral lung cancer in patients with breast cancer (RR = 1.27, p = 0.001). CONCLUSIONS: Patients with breast cancer are more likely to develop lung cancer than the general population, and the risk of developing primary lung cancer after breast cancer is affected by smoking, radiotherapy, chemotherapy, estrogen receptor status and progesterone receptor status.
引用
- Wang Y, Li J, Chang S, et al. Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases. J Thorac Oncol. 2021. PMID: 34256110. doi:10.1016/j.jtho.2021.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。